Levosert One

Levonorgestrel, the active ingredient in Levosert One, is a progestogen presented as an intrauterine system (IUS) for intrauterine placement. It releases a low, continuous dose of levonorgestrel directly into the uterine cavity, providing effective, long‑acting reversible contraception for women of reproductive age and reducing the need for daily oral dosing.

GNH USA supplies Levosert One as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets to meet local health authority requirements.

Levonorgestrel is a progestogen used in hormonal contraception to prevent pregnancy. - Contraception: Provides long‑acting reversible contraception for up to several years when placed intrauterinely. - Unintended pregnancy prevention: Reduces the risk of unintended pregnancy in sexually active women. - Menstrual regulation: Can lead to lighter, more predictable menstrual bleeding in many users.

Levosert One may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular bleeding or spotting: unpredictable menstrual bleeding patterns. - Amenorrhea: absence of menstrual periods. - Pelvic or abdominal cramping: discomfort in the lower abdomen. - Device expulsion: partial or complete displacement of the IUS. - Headache: mild to moderate intensity. - Breast tenderness: soreness or swelling of breast tissue.

Serious or Rare Side Effects: - Uterine perforation: rare injury to the uterine wall during insertion. - Pelvic infection: severe infection requiring medical treatment. - Ectopic pregnancy: pregnancy occurring outside the uterus. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hormonal migraine: intense migraine linked to hormonal changes. - Heavy vaginal discharge: persistent, foul‑smelling discharge.

Before using Levosert One, clinicians should assess patient suitability and counsel on potential risks. - Contraindications: Do not insert in women with active pelvic infection, unexplained vaginal bleeding, or known uterine anomalies. - Pregnancy testing: Ensure the patient is not pregnant before insertion. - Follow‑up: Schedule a post‑insertion check to confirm correct placement. - Medication review: Evaluate concurrent use of drugs that may affect levonorgestrel levels. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Levonorgestrel levels can be altered by other medicines, requiring monitoring.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin, phenytoin): may significantly reduce contraceptive efficacy. - Simultaneous use of another hormonal IUD: increases risk of hormonal side effects.

Moderate Interactions (Monitor Closely): - Antibiotics such as rifampin: may lower levonorgestrel concentrations. - Antifungal agents (e.g., ketoconazole): can increase levonorgestrel exposure. - Herbal supplements like St. John’s wort: may decrease effectiveness. - Antiretroviral drugs (e.g., efavirenz): may reduce contraceptive reliability.